Roche Backs Off Mircera Suit In India
Executive Summary
Roche has dropped its suit against Intas Pharmaceuticals Ltd. over the alleged infringement of its patents pertaining to Mircera (methoxy polyethylene glycol-epoetin beta), after the Indian firm apparently established that its product is "different". Both sides, though, seemed to keep the matter alive, suggesting that they would seek appropriate remedies in the event of fresh "cause of action".
You may also be interested in...
Indian Avastin Versions Head For Debut; Watch Off-Label Space
Cut-price versions of Roche's anticancer, Avastin (bevacizumab), may well be on their way to the Indian market after a key local expert panel recently recommended the biosimilars for marketing. And "improvements" to facilitate off-label use of the product also appear to be on the agenda of some biosimilar players.
Indian Herceptin Biosimilars Case Simmers
The hotly contested case concerning biosimilar versions of Roche's Herceptin (trastuzumab) witnessed a seesaw shift after a division bench of the Delhi High Court held that the status prevailing prior to a stinging April 25 order against Biocon Ltd. and Mylan NV will continue to operate.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.